Suzuki Hidenori, Taniguchi Hiroya, Inaba Yoshitaka, Tachibana Hiroyuki, Beppu Shintaro, Terada Hoshino, Kobayashi Yoshiaki, Hanai Nobuhiro
Department of Head and Neck Surgery, Aichi Cancer Center, Nagoya, Japan
Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan.
Anticancer Res. 2025 Sep;45(9):3877-3884. doi: 10.21873/anticanres.17746.
BACKGROUND/AIM: Systemic therapy for olfactory neuroblastoma with unresectable multi-recurrence disease is unestablished. However, peptide receptor radionuclide therapy (PRRT) with 177Lu-pentetreotide is considered to be an effective systemic treatment for unresectable multi-recurrence olfactory neuroblastoma expressing somatostatin receptors. This study investigated the association between survival outcome and treatment modality in olfactory neuroblastoma, with a focus on peptide receptor radionuclide therapy.
Twenty-three patients with olfactory neuroblastoma who underwent initial definitive treatment from 1998 to 2023 were enrolled in this retrospective study.
Patients who underwent surgery were significantly associated with longer local recurrence-free survival from the initial definitive treatment compared to those who underwent radiotherapy. Among 18 patients with residual disease or first recurrence, those with distant metastasis related significantly with shorter overall survival from the diagnosis day of residual disease/first recurrence. Among 11 patients with unresectable multi-recurrent olfactory neuroblastoma, the 3 patients who received PRRT had significantly longer overall survival from the time of diagnosis compared to the 8 patients who did not receive PRRT.
PRRT was associated with improved survival in patients with unresectable multi-recurrent olfactory neuroblastoma.
背景/目的：对于无法切除的多复发嗅神经母细胞瘤，全身治疗方法尚未确立。然而，用177Lu-奥曲肽进行肽受体放射性核素治疗（PRRT）被认为是治疗表达生长抑素受体的无法切除的多复发嗅神经母细胞瘤的一种有效的全身治疗方法。本研究调查了嗅神经母细胞瘤的生存结局与治疗方式之间的关联，重点是肽受体放射性核素治疗。
本回顾性研究纳入了1998年至2023年期间接受初始确定性治疗的23例嗅神经母细胞瘤患者。
与接受放疗的患者相比，接受手术的患者从初始确定性治疗开始的局部无复发生存期显著更长。在18例有残留疾病或首次复发的患者中，有远处转移的患者从残留疾病/首次复发诊断日起的总生存期显著更短。在11例无法切除的多复发嗅神经母细胞瘤患者中，与未接受PRRT的8例患者相比，接受PRRT的3例患者从诊断时起的总生存期显著更长。
PRRT与无法切除的多复发嗅神经母细胞瘤患者的生存改善相关。
